Media Releases

77 items found

Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials

Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials
March 3, 2026

TOKYO AND PRINCETON, Japan and the U.S., 3 March 2026 — Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the discontinuation of all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody being evaluated for potential indicati...

Read more

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

January 30, 2026

Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman

December 11, 2025

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

December 8, 2025

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

November 25, 2025

Kyowa Kirin to Present New Research Highlighting Mogamulizumab’s Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting

November 18, 2025

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

November 13, 2025

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

November 3, 2025

KURA ONCOLOGY AND KYOWA KIRIN LAUNCH CLINICAL TRIAL EVALUATING DUAL INHIBITION OF NPM1 AND FLT3 MUTATIONS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)

October 1, 2025

KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE FIRST PATIENT DOSED IN PIVOTAL PHASE 3 KOMET-017 TRIAL OF ZIFTOMENIB FOR FRONTLINE ACUTE MYELOID LEUKEMIA (AML)

September 29, 2025